vs
Side-by-side financial comparison of Sight Sciences, Inc. (SGHT) and UNITY BANCORP INC (UNTY). Click either name above to swap in a different company.
UNITY BANCORP INC is the larger business by last-quarter revenue ($35.3M vs $20.4M, roughly 1.7× Sight Sciences, Inc.). UNITY BANCORP INC runs the higher net margin — 43.9% vs -20.4%, a 64.3% gap on every dollar of revenue. On growth, UNITY BANCORP INC posted the faster year-over-year revenue change (24.2% vs 6.9%). UNITY BANCORP INC produced more free cash flow last quarter ($44.3M vs $-2.0M). Over the past eight quarters, UNITY BANCORP INC's revenue compounded faster (17.5% CAGR vs 2.9%).
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
Unity Bancorp Inc is a New Jersey-headquartered financial holding company operating Unity Bank. It offers a full range of commercial and retail banking services including business loans, deposit products, mortgage services, and personal banking solutions, primarily serving small and medium-sized enterprises and individual consumers across local communities in New Jersey and eastern Pennsylvania.
SGHT vs UNTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $35.3M |
| Net Profit | $-4.2M | $15.5M |
| Gross Margin | 87.3% | — |
| Operating Margin | -18.0% | 55.8% |
| Net Margin | -20.4% | 43.9% |
| Revenue YoY | 6.9% | 24.2% |
| Net Profit YoY | 64.9% | 34.5% |
| EPS (diluted) | $-0.07 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | $35.3M | ||
| Q3 25 | $19.9M | $32.8M | ||
| Q2 25 | $19.6M | $34.4M | ||
| Q1 25 | $17.5M | $29.4M | ||
| Q4 24 | $19.1M | $28.4M | ||
| Q3 24 | $20.2M | $27.7M | ||
| Q2 24 | $21.4M | $25.5M | ||
| Q1 24 | $19.3M | $25.6M |
| Q4 25 | $-4.2M | $15.5M | ||
| Q3 25 | $-8.2M | $14.4M | ||
| Q2 25 | $-11.9M | $16.5M | ||
| Q1 25 | $-14.2M | $11.6M | ||
| Q4 24 | $-11.8M | $11.5M | ||
| Q3 24 | $-11.1M | $10.9M | ||
| Q2 24 | $-12.3M | $9.5M | ||
| Q1 24 | $-16.3M | $9.6M |
| Q4 25 | 87.3% | — | ||
| Q3 25 | 86.4% | — | ||
| Q2 25 | 84.8% | — | ||
| Q1 25 | 86.2% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | 83.9% | — | ||
| Q2 24 | 85.8% | — | ||
| Q1 24 | 85.5% | — |
| Q4 25 | -18.0% | 55.8% | ||
| Q3 25 | -39.7% | 57.5% | ||
| Q2 25 | -59.6% | 62.6% | ||
| Q1 25 | -79.2% | 52.6% | ||
| Q4 24 | -62.5% | 51.0% | ||
| Q3 24 | -55.7% | 52.7% | ||
| Q2 24 | -59.2% | 49.3% | ||
| Q1 24 | -76.4% | 50.0% |
| Q4 25 | -20.4% | 43.9% | ||
| Q3 25 | -41.0% | 43.8% | ||
| Q2 25 | -61.0% | 48.0% | ||
| Q1 25 | -80.8% | 39.5% | ||
| Q4 24 | -62.1% | 40.5% | ||
| Q3 24 | -54.9% | 39.4% | ||
| Q2 24 | -57.7% | 37.1% | ||
| Q1 24 | -84.4% | 37.5% |
| Q4 25 | $-0.07 | $1.52 | ||
| Q3 25 | $-0.16 | $1.41 | ||
| Q2 25 | $-0.23 | $1.61 | ||
| Q1 25 | $-0.28 | $1.13 | ||
| Q4 24 | $-0.23 | $1.13 | ||
| Q3 24 | $-0.22 | $1.07 | ||
| Q2 24 | $-0.25 | $0.92 | ||
| Q1 24 | $-0.33 | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.0M | — |
| Total DebtLower is stronger | $42.4M | — |
| Stockholders' EquityBook value | $63.9M | $345.6M |
| Total Assets | $115.3M | $3.0B |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.0M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $101.5M | — | ||
| Q1 25 | $108.8M | — | ||
| Q4 24 | $120.4M | — | ||
| Q3 24 | $118.6M | — | ||
| Q2 24 | $118.2M | — | ||
| Q1 24 | $127.3M | — |
| Q4 25 | $42.4M | — | ||
| Q3 25 | $42.4M | — | ||
| Q2 25 | $42.4M | — | ||
| Q1 25 | $42.4M | — | ||
| Q4 24 | $40.0M | $230.8M | ||
| Q3 24 | $37.1M | — | ||
| Q2 24 | $35.0M | — | ||
| Q1 24 | $35.0M | — |
| Q4 25 | $63.9M | $345.6M | ||
| Q3 25 | $64.3M | $334.0M | ||
| Q2 25 | $70.0M | $319.8M | ||
| Q1 25 | $77.6M | $306.1M | ||
| Q4 24 | $87.5M | $295.6M | ||
| Q3 24 | $95.0M | $284.3M | ||
| Q2 24 | $101.6M | $273.4M | ||
| Q1 24 | $109.2M | $266.8M |
| Q4 25 | $115.3M | $3.0B | ||
| Q3 25 | $116.3M | $2.9B | ||
| Q2 25 | $122.0M | $2.9B | ||
| Q1 25 | $129.7M | $2.8B | ||
| Q4 24 | $142.8M | $2.7B | ||
| Q3 24 | $143.6M | $2.6B | ||
| Q2 24 | $149.7M | $2.6B | ||
| Q1 24 | $155.6M | $2.6B |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.46× | 0.78× | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $44.9M |
| Free Cash FlowOCF − Capex | $-2.0M | $44.3M |
| FCF MarginFCF / Revenue | -9.7% | 125.7% |
| Capex IntensityCapex / Revenue | 0.8% | 1.6% |
| Cash ConversionOCF / Net Profit | — | 2.90× |
| TTM Free Cash FlowTrailing 4 quarters | — | $81.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.8M | $44.9M | ||
| Q3 25 | $-8.7M | $45.5M | ||
| Q2 25 | $-7.5M | $-25.3M | ||
| Q1 25 | $-11.6M | $17.9M | ||
| Q4 24 | $-3.5M | $48.0M | ||
| Q3 24 | $362.0K | $17.7M | ||
| Q2 24 | $-9.5M | $-8.4M | ||
| Q1 24 | $-9.8M | $15.8M |
| Q4 25 | $-2.0M | $44.3M | ||
| Q3 25 | $-8.9M | $45.3M | ||
| Q2 25 | $-7.8M | $-25.5M | ||
| Q1 25 | — | $17.6M | ||
| Q4 24 | $-3.6M | $47.3M | ||
| Q3 24 | $311.0K | $17.5M | ||
| Q2 24 | $-9.5M | $-8.6M | ||
| Q1 24 | $-9.9M | $15.7M |
| Q4 25 | -9.7% | 125.7% | ||
| Q3 25 | -44.7% | 138.1% | ||
| Q2 25 | -39.6% | -74.2% | ||
| Q1 25 | — | 59.9% | ||
| Q4 24 | -18.9% | 166.5% | ||
| Q3 24 | 1.5% | 63.3% | ||
| Q2 24 | -44.7% | -33.7% | ||
| Q1 24 | -51.4% | 61.4% |
| Q4 25 | 0.8% | 1.6% | ||
| Q3 25 | 0.9% | 0.7% | ||
| Q2 25 | 1.1% | 0.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.7% | 2.4% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 0.6% | 0.3% |
| Q4 25 | — | 2.90× | ||
| Q3 25 | — | 3.16× | ||
| Q2 25 | — | -1.54× | ||
| Q1 25 | — | 1.54× | ||
| Q4 24 | — | 4.17× | ||
| Q3 24 | — | 1.62× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | — | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
UNTY
Segment breakdown not available.
